1. ���ݾ���������ҽԺƤ����
2. ���ݾ���������ҽԺ

��ժҪ�� Ŀ�� ̽�ֵ����������������������ƶ������չ�����ٴ���Ч�� ���� 137���������չ���������Ϊ2�飺������69�������������������ɢƬ5 mg��ÿ��1�Σ�������Ƭ 200 mg��ÿ��3�Σ�������68��������ɳ���Ȱ�Ƭ50 mg��ÿ��2�Σ�������Ƭ200 mg��ÿ��3�Ρ����黼��ͬʱ���踴������������ã�ÿ��2�Σ�4��Ϊ1���Ƴ̡�Ҫ�����л��������ڼ��ɹ���ֱ������ƿ�ʼǰ��D0�������ƿ�ʼ��ÿ2�ܣ�D14��D28���������ߵ�֢״�����½�ָ����SSRI����Ȭ���ʼ�����Ч�ʡ����ƹ����м�¼������Ӧ��������ȫ�ԡ� ��� ����119��������飬����������61����������58������D14��D28��������SSRI�ֱ�Ϊ0.81 ± 0.23��0.92 ± 0.11��Ȭ���ʷֱ�Ϊ47.54%��70.49%������Ч�ʷֱ�Ϊ80.33%��93.44%��������飨SSRI�ֱ�Ϊ0.87 ± 0.17��0.97 ± 0.23��Ȭ���ʷֱ�Ϊ48.28%��72.41%������Ч�ʷֱ�Ϊ84.48%��91.38%���Ƚϣ�������ͳ��ѧ���壨��P > 0.05�������ֻ��߷���������Ӧ�������ܣ������鲻����Ӧ�������������ڶ����飨P < 0.01���� ���� ������������ɢƬ��������Ƭ���ƶ������չ����ٴ���Чȷ�У���ɳ���Ȱ���Ч�൱��������Ӧ�������������١�

Yang Guilan*, Zhao Min, Pan Zhi, Xiao Hui, Long Chaoqin, Gao Jian, He Chunfeng, Bai Jingrui. *Department of Dermatology, Lanzhou General Hospital, Lanzhou Military Area Command, Lanzhou 730050, China Corresponding author: Yang Guilan, Email: drgly2006@126.com ��Abstract�� Objective To estimate the efficacy of desloratadine combined with nicotinamide for the treatment of polymorphous light eruption ��PLE��. Methods One hundred and thirty-seven patients with PLE were enrolled in this study, and randomly divided into two groups: test group ��n = 69�� treated with oral desloratadine dispersible tablets ��5 mg once daily�� and nicotinamide tablets ��200 mg thrice daily��, control group ��n = 68�� treated with thalidomide tablets ��50 mg twice daily�� and nicotinamide tablets ��200 mg thrice daily��. All the patients topically applied compound boric acid ointment twice daily, and were requested to adopt sun-protection measures during the treatment. All the treatments lasted 4 weeks. Symptom score was estimated for the patients before treatment and on day 14 and 28 after the start of treatment. The efficacy was evaluated according to symptom score reduction index��SSRI��, cure rate and total response rate, and safety was assessed based on adverse reactions during the treatment. Results One hundred and nineteen patients��61 in the test group and 58 in the control group�� completed the trial. No significant differences were observed between the test group and control group in SSRI ��day 14: 0.81 ± 0.23 vs. 0.87 ± 0.17; day 28: 0.92 ± 0.11 vs. 0.97 ± 0.23, both P > 0.05��, cure rate ��day 14: 47.54% vs. 48.28%; day 28: 70.49% vs. 72.41%, both P > 0.05�� or total response rate ��day 14: 80.33% vs. 84.48%; day 28: 93.44% vs. 91.38%, both P > 0.05��. Adverse reactions were observed in some patients, but were tolerable, and their incidence rate was significantly lower in the test group than in the control group ��P < 0.01��. Conclusion Compared with thalidomide plus nicotinamide, desloratadine combined with nicotinamide show equivalent efficacy in the treatment of PLE with reduced incidence of adverse reactions.

����ʡ��Ȼ��ѧ����